Education
About Us
Working with TipRanks
Follow Us
Sernova (TSE:SVA)
TSX:SVA
SVA Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.15 - C$0.47
Previous CloseN/A
Volume71.45K
Average Volume (3M)136.76K
Market Cap
C$65.70M
Enterprise ValueC$71.38M
Total Cash (Recent Filing)C$1.21M
Total Debt (Recent Filing)C$546.47K
Price to Earnings (P/E)―
Beta-0.69
Next Earnings
Jun 25, 2025EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding328,484,770
10 Day Avg. Volume96,846
30 Day Avg. Volume136,760
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$6.00Price Target Upside2900.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Sernova News
PremiumCompany Announcements
Sernova Advances Clinical Trial for Diabetes Treatment with Promising Results
PremiumCompany Announcements
Sernova Biotherapeutics Secures FDA Clearance for Thyroid Cell Therapy Trial
PremiumCompany Announcements
Sernova Submits IND for Cell Pouch Hybrid Organ in Hypothyroidism Treatment
PremiumCompany Announcements
Sernova Biotherapeutics Appoints New Chair and Rebrands
PremiumCompany Announcements
Sernova Advances Diabetes Cure with Strategic Initiatives---
Bulls Say, Bears Say
Bulls Say
Business DevelopmentThere is a high potential for business development, such as major partnership or acquisition.
Clinical TrialsPositive preclinical results justify further exploration with a planned first-in-human clinical trial to assess safety, tolerability, and efficacy in hypothyroidism.
Market OpportunitySubmission of an IND application for the Cell Pouch device in hypothyroidism could address a significant market opportunity estimated at approximately $2.2 billion.
Bears Say
Clinical DependencyA Phase 1/2 multi-cohort study is currently ongoing in T1D patients who are insulin dependent for more than 5 years.
Drug DependencySernova's Cell Pouch device aims to reduce or eliminate the need for lifelong thyroid medications and improve quality of life for hypothyroidism patients.
---
Options Prices
Currently, No data available
---
Ownership Overview
4.10% Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
95.90% Public Companies and
Individual Investors
SVA FAQ
What was Sernova’s price range in the past 12 months?
Sernova lowest stock price was C$0.15 and its highest was C$0.47 in the past 12 months.
What is Sernova’s market cap?
Sernova’s market cap is C$65.70M.
When is Sernova’s upcoming earnings report date?
Sernova’s upcoming earnings report date is Jun 25, 2025 which is in 66 days.
How were Sernova’s earnings last quarter?
Sernova released its earnings results on Mar 14, 2025. The company reported -C$0.015 earnings per share for the quarter, beating the consensus estimate of -C$0.028 by C$0.013.
Is Sernova overvalued?
According to Wall Street analysts Sernova’s price is currently Undervalued.
Does Sernova pay dividends?
Sernova does not currently pay dividends.
What is Sernova’s EPS estimate?
Sernova’s EPS estimate is -0.01.
How many shares outstanding does Sernova have?
Sernova has 328,484,770 shares outstanding.
What happened to Sernova’s price movement after its last earnings report?
Sernova reported an EPS of -C$0.015 in its last earnings report, beating expectations of -C$0.028. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sernova?
Currently, no hedge funds are holding shares in TSE:SVA
---
Company Description
Sernova
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.
---
SVA Stock 12 Month Forecast
Average Price Target
C$6.00
▲(2900.00% Upside)
Technical Analysis
Best Analysts Covering SVA
1 Year
1 Year Success Rate
0/11 ratings generated profit
1 Year Average Return
-45.45%
reiterated a buy rating 7 months ago
Copying Stefan Quenneville's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -45.45% per trade.
---